Clinical trials: CNS Germ Cell Tumor
Glioblastoma, Brain Tumor
A Study of Maprotiline in Combination With Tamoxifen and Temozolomide for Recurrent Glioblastoma
The main purpose of this study is to find out the highest possible dose of maprotiline that can be given safely in combination with temozolomide and tamoxifen.
- Trial name
- NCT04200066
- Testing
- Temozolomide, Tamoxifen, Maprotiline
- Sponsor
- University of Rochester
Brain and Central Nervous System Tumors, Neuroblastoma
Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer
The purpose of this study is to test the feasibility and toxicity of administering intrathecal immunotherapy for patients with central nervous system/leptomeningeal (CNS/LM) malignancies.
- Conditions
- Brain and Central Nervous System Tumors, Neuroblastoma, Sarcoma
- Trial name
- NCT00089245
- Testing
- Iodine I 131 MOAB 8H9
- Where
- United States
- Volunteers
- 177 people
- Sponsor
- Y-mAbs Therapeutics
Glioblastoma
Exercise in Patients With Glioblastoma
Patients with newly-diagnosed GBM will be given personalized exercise regimes during concurrent chemo-radiation and up to 3 months later.
- Trial name
- NCT03390569
- Testing
- Exercise
- Where
- Canada
- Volunteers
- 54 people
- Sponsor
- University Health Network, Toronto
Glioblastoma Multiforme, Glioma
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
In this study, investigators will conduct a phase I/II trial in recurrent (temozolomide resistant) glioma patients. The overall goal of this study is to provide a foundation for future studies with indoximod tested in newly…
- Conditions
- Glioblastoma Multiforme, Glioma, Gliosarcoma, Malignant Brain Tumor
- Trial name
- NCT02052648
- Testing
- Indoximod, Temozolomide, Bevacizumab
- Where
- 17 sites in United States
- Volunteers
- 160 people
- Sponsor
- NewLink Genetics Corporation
Brain and Central Nervous System Tumors
Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide and celecoxib may stop the growth of tumor cells by stopping blood flow to the tumor and may…
- Trial name
- NCT00047294
- Testing
- celecoxib, temozolomide, thalidomide
- Where
- 4 sites in United States
- Sponsor
- Dana-Farber Cancer Institute
Brain and Central Nervous System Tumors
Phenylacetate in Treating Children With Recurrent or Progressive Brain Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of phenylacetate in treating children with recurrent or…
- Trial name
- NCT00003241
- Testing
- phenylacetate
- Where
- 6 sites in United States
- Sponsor
- Texas Children's Cancer Center
Brain Cancer, HGG
Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)
High-grade gliomas (HGGs) are among the most aggressive and treatment-resistant brain tumors. Immunotherapy with checkpoint inhibitors like nivolumab has shown promise, but its efficacy remains variable and poorly understood in…
- Conditions
- Brain Cancer, HGG, Glioma, High Grade Glioma
- Trial name
- NCT07210632
- Testing
- Nivolumab, Nivolumab-IRDye800
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Eben Rosenthal
Malignant Glioma, Glioblastoma Multiforme
Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients
IL13-PE38QQR is an oncology drug product consisting of IL13 (interleukin-13) and PE38QQR (a bacteria toxin). IL3-PE38QQR is a protein that exhibits cell killing activity against a variety of IL13 receptor-positive tumor cell…
- Conditions
- Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, Mixed Oligoastrocytoma
- Trial name
- NCT00024557
- Testing
- IL13-PE38QQR, targeted fusion protein therapy, surgery
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- INSYS Therapeutics Inc
Glioblastoma, MGMT-Unmethylated Glioblastoma
Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
This Phase I study investigated the side-effects and best dose of microtubule-targeted agent BAL101553 when given together with radiation therapy in treating patients with newly-diagnosed O6-methylguanine-DNA methyltransferase…
- Trial name
- NCT03250299
- Testing
- Microtubule-Targeted Agent BAL101553, Radiation Therapy
- Where
- 8 sites in United States
- Volunteers
- 26 people
- Sponsor
- Basilea Pharmaceutica
Spinal Metastases, Vertebral Metastases
Stereotactic Body Radiotherapy for Spine Tumors
This study will evaluate the local control rate as well as acute and late toxicity rates of stereotactic body radiotherapy (SBRT) for the treatment of spine metastases and benign spine tumors.
- Conditions
- Spinal Metastases, Vertebral Metastases, Benign Spinal Tumors, Chordoma
- Trial name
- NCT01347307
- Testing
- SBRT for Benign Extradural Spine Tumors, SBRT for Vertebral/Paraspinal Metastases
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Mercy Research
Advanced Solid Tumors
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-706 as a monotherapy…
- Trial name
- NCT05599984
- Testing
- ABBV-706, Cisplatin, Budigalimab
- Where
- 66 sites in United States, Australia and 8 more
- Volunteers
- 288 people
- Sponsor
- AbbVie
Glioblastoma, Glial Tumor
Evaluation of the CONVIVO System
The primary objective of this study is to evaluate the diagnostic performance of the CONVIVO confocal endomicroscope in discriminating between normal and abnormal tissue in vivo during brain tumor surgery.
- Conditions
- Glioblastoma, Glial Tumor, Brain Metastases, Meningioma
- Trial name
- NCT05139277
- Testing
- CONVIVO system, Conventional histologic evaluation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Anaplastic Astrocytoma, Diffuse Brainstem Glioma
Testing Cerebrospinal Fluid for Cell-free Tumor DNA in Children, Adolescents, and Young Adults With Brain Tumors
Recent advances in technology have allowed for the detection of cell-free DNA (cfDNA). cfDNA is tumor DNA that can be found in the fluid that surrounds the brain and spinal cord (called cerebrospinal fluid or CSF) and in the…
- Conditions
- Anaplastic Astrocytoma, Diffuse Brainstem Glioma, Glioblastoma Multiforme, High-grade Astrocytoma NOS
- Trial name
- NCT05934630
- Where
- 10 sites in United States, Canada
- Volunteers
- 57 people
- Sponsor
- Pediatric Brain Tumor Consortium
GBM, DIPG Brain Tumor
Clinical Study of Allogeneic Vγ9Vδ2 T Cells in the Treatment of Brain Malignant Glioma
Primary brain malignant tumor has become the first lethal tumor in children and young adults, and the treatment is limited, and the prognosis of patients is poor.
- Conditions
- GBM, DIPG Brain Tumor, Medulloblastoma
- Trial name
- CSAγδTBMG (NCT06396481)
- Testing
- Vγ9Vδ2 T cell
- Where
- China
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Beijing Tiantan Hospital
Brain Metastases, MRI
Detection and Metabolic Characterization in DOPA PET/CT of Brain Metastases
About 20 to 30% of patients treated for cancer will have brain metastases. These brain metastases are found more frequently in patients with lung cancer, breast cancer or melanoma.
- Trial name
- DOPACER (NCT04890028)
- Testing
- F-DOPA PET/CT
- Where
- 3 sites in France
- Volunteers
- 32 people
- Sponsor
- Institut Cancerologie de l'Ouest
High-Grade Glioma (HGG), Posterior Fossa-A Ependymoma
A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma
This study is researching an experimental drug called cemiplimab (called "study drug") and the combination of experimental drugs of fianlimab and cemiplimab (called "study drugs").
- Trial name
- NCT07567469
- Testing
- Cemiplimab, Cemiplimab+Fianlimab Fixed Dose Combination (FDC)
- Volunteers
- 120 people
- Sponsor
- Regeneron Pharmaceuticals
Diffuse Intrinsic Pontine Glioma, Brainstem Glioma
Molecular Analysis of Samples From Patients With Diffuse Intrinsic Pontine Glioma and Brainstem Glioma
The purpose of this study is to prospectively collect specimens from pediatric patients with diffuse intrinsic pontine glioma or brainstem glioma, either during therapy or at autopsy, in order to characterize the molecular…
- Trial name
- NCT01106794
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Children's National Research Institute
Glioblastoma Multiforme, Anaplastic Astrocytoma
Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas
In this study an investigational replication-defective, recombinant adenovirus expressing the interferon-beta gene (BG00001) will be directly injected into tumors, in patients with recurrent Grade III and Grade IV Gliomas, in…
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma, Oligoastrocytoma, Mixed, Gliosarcoma
- Trial name
- NCT00031083
- Testing
- Interferon-beta
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- Biogen
Glioblastoma Multiforme
Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) Patients
The purpose of this study is to determine whether the addition of an investigational medication, axitinib, to radiation therapy will improve the outcome of treatment in patients, above the age of 70.
- Trial name
- NCT01508117
- Testing
- Axitinib, Radiation Therapy
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Cincinnati
Recurrent Glioblastoma
RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM)
This is a Phase I study to demonstrate the manufacturing feasibility and safety, and to determine the maximum tolerated dose (MTD) of RNA-LP vaccines in adult patients with recurrent glioblastoma.
- Trial name
- ASPIRE (NCT06389591)
- Testing
- pp65 RNA loaded lipid particles, pp65 RNA-LPs (Drug Product 1 or DP1), RNA loaded lipid particles, RNA-LPs (Drug Product 2 or DP2)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Florida
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.